MyopiaNCT07909720
The EYERISING Study
A study testing Repeated Low-Level Red Light (RLRL) therapy in people with Myopia and Astigmatism, run by University of Wisconsin, Madison at 2 sites in 2 countries.
Trial summary
The purpose of this clinical trial is to see if and how well Repeated Low-Level Red Light (RLRL) therapy works to control myopia over 12 months. The main question it aims to answer is: Can RLRL therapy help slow down the worsening of myopia? Participants will use a red-light therapy investigational device at home, 5… Read more about this study
- Who is it for?
- Ages 6 to 12 years
- Conditions the study is for
- Myopia, Astigmatism, Anisometropia
- What is being tested?
- Repeated Low-Level Red Light (RLRL) therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 333 participants
- Where
- 2 sitesin 2 countries
- Study dates
- Oct 2026to Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age ≥ 6 and ≤ 12 (at screening)
- Myopia: Cycloplegic SER -1.0 to -7.0 D
- Astigmatism: < 1.5 D
- Anisometropia: < 1.5 D
- Informed parental consent
- Consistent access to wireless internet
Who cannot join
- A subject who is born female and who is currently menstruating or has begun menstruation (menarche).
- Ophthalmic diseases, conditions, or syndromes other than refractive errors
- Previous use of treatment for myopia control (e.g., defocusing lenses or contact lenses, orthokeratology, atropine, and pirenzepine)
- Any previous ocular surgery
- Systemic diseases (e.g., endocrine, cardiac diseases) and developmental anomalies
- Inability to attend regular follow up visits
- Participants with any symptom, disease, or other condition that, in the opinion of the investigators, may affect the effectiveness of the investigational treatment and/or the ability of the participant to complete study activities
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
United States1 site
University of Wisconsin - Madison
Madison, Wisconsin, 53715
Angie Adler, 608-265-7557, amadler1@wisc.edu
Yasmin Bradfield, MD
Nepal1 site
Tilganga Institute of Ophthalmology
Kathmandu, Bagmati Province
Srijana Adhikari, srij_a@yahoo.com
Srijana Adhikari
About this study
Official title: Repeated Low-level Red Light for Myopia Progression Study: An International, Multicenter, Multiethnic, Randomized Controlled Trial, IPOSC Study
The purpose of this clinical trial is to see if and how well Repeated Low-Level Red Light (RLRL) therapy works to control myopia over 12 months. The main question it aims to answer is:
- Can RLRL therapy help slow down the worsening of myopia?
Participants will use a red-light therapy investigational device at home, 5 days a week for 12 months.
- Conditions
- Myopia, Astigmatism, Anisometropia
- Being tested
- Repeated Low-Level Red Light (RLRL) therapy, Placebo Device
- Medical subject headings
- Myopia, Astigmatism, Anisometropia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Repeated Low-Level Red Light (RLRL) therapyDevice
RLRL device emits low-level red-light with a wavelength of 650 ± 10 nm. The device provides light at a power of 2.00 ± 0.50 mW.
Placebo DeviceDevice
Placebo device will match the RLRL in appearance but will not emit light.
| Study group | Role | What they receive |
|---|---|---|
| Red light therapy | Experimental | Participants will receive red light therapy Receives: Device: Repeated Low-Level Red Light (RLRL) therapy |
| Placebo | Placebo comparator | Participants will receive placebo therapy Receives: Device: Placebo Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cycloplegic spherical equivalent refraction (SER)
SER will be measured using an autorefractometer after eye drops are given to temporarily relax the eye's focusing muscles. SER, measured in diopters (D), represents the amount of nearsightedness and will be used to measure the change in myopia from baseline.
Measured: Baseline, 4 months, 8 months, 12 months
Change in axial length (AL)
AL will be measured using the IOLMaster and reported in millimeters (mm). Change in AL from baseline will be used to assess ocular growth/myopia progression.
Measured: Baseline, 4 months, 8 months, 12 months
Secondary outcomes (12)
Change in rate of SER increase
Measured: Baseline, 4 months, 8 months, 12 months
Change in rate of AL increase
Measured: Baseline, 4 months, 8 months, 12 months
Best corrected visual acuity (BCVA)
Measured: Baseline, 4 months, 8 months, 12 months
Change in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) composite score
The NEI VFQ-25 is a 25-item questionnaire assessing vision-related functioning and quality of life. The composite score ranges from 0 to 100, with higher scores indicating better visual functioning and vision-related quality of life.
Measured: Baseline, 4 months, 8 months, 12 months
Change in anterior chamber depth (ACD)
Measured: Baseline, 4 months, 8 months, 12 months
Change in corneal curvature (CC)
Measured: Baseline, 4 months, 8 months, 12 months
Change in choroidal thickness (CT)
Measured: Baseline, 4 months, 8 months, 12 months
Change in White-to-White (WTW)
Measured: Baseline, 4 months, 8 months, 12 months
Change in choroidal structures
Measured: Baseline, 4 months, 8 months, 12 months
Intraocular pressure (IOP)
Measured: Baseline, 4 months, 8 months, 12 months
Ocular and systemic symptoms
Measured: Baseline, 4 months, 8 months, 12 months
Ocular signs assessed by slit-lamp biomicroscopy and binocular indirect ophthalmoscopy
Measured: Baseline, 4 months, 8 months, 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study startOct 2026 (estimated)
- Primary completionMar 2029 (estimated)
- Study completionMar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyopiaStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 333 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yasmin Bradfield, MD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07909720
- Sponsor's protocol ID
- 2025-1264
- Other IDs
- UWMSN | SMPH | Ophthalmology a, AS, Protocol Version 8/22/2025
- Status last verified
- Dec 2025
- First submitted
- 27 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Repeated Low-level Red Light for Myopia Progression Study: An International, Multicenter, Multiethnic, Randomized Controlled Trial, IPOSC Study
- ClinicalTrials.gov ID
- NCT07909720
- Acronym / sponsor ID
- 2025-1264
- Conditions
- Myopia, Astigmatism, Anisometropia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 333 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Mar 2029 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical trial is to see if and how well Repeated Low-Level Red Light (RLRL) therapy works to control myopia over 12 months. The main question it aims to answer is:
- Can RLRL therapy help slow down the worsening of myopia?
Participants will use a red-light therapy investigational device at home, 5 days a week for 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Red light therapy | Experimental | Device: Repeated Low-Level Red Light (RLRL) therapyParticipants will receive red light therapy |
| Placebo | Placebo comparator | Device: Placebo DeviceParticipants will receive placebo therapy |
Who may qualify
- Ages
- 6 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Age ≥ 6 and ≤ 12 (at screening)
- Myopia: Cycloplegic SER -1.0 to -7.0 D
- Astigmatism: < 1.5 D
- Anisometropia: < 1.5 D
- Informed parental consent
Key exclusion criteria (7 listed)
- A subject who is born female and who is currently menstruating or has begun menstruation (menarche).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Repeated Low-Level Red Light (RLRL) therapyRLRL device emits low-level red-light with a wavelength of 650 ± 10 nm. The device provides light at a power of 2.00 ± 0.50 mW. | Device | Red light therapy |
| Placebo DevicePlacebo device will match the RLRL in appearance but will not emit light. | Device | Placebo |
Primary outcome
Change in cycloplegic spherical equivalent refraction (SER)
Time frame: Baseline, 4 months, 8 months, 12 months
SER will be measured using an autorefractometer after eye drops are given to temporarily relax the eye's focusing muscles. SER, measured in diopters (D), represents the amount of nearsightedness and will be used to measure the change in myopia from baseline.
Change in axial length (AL)
Time frame: Baseline, 4 months, 8 months, 12 months
AL will be measured using the IOLMaster and reported in millimeters (mm). Change in AL from baseline will be used to assess ocular growth/myopia progression.
12 secondary outcomes
Change in rate of SER increase
Time frame: Baseline, 4 months, 8 months, 12 months
Change in rate of AL increase
Time frame: Baseline, 4 months, 8 months, 12 months
Best corrected visual acuity (BCVA)
Time frame: Baseline, 4 months, 8 months, 12 months
Change in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) composite score
Time frame: Baseline, 4 months, 8 months, 12 months
Change in anterior chamber depth (ACD)
Time frame: Baseline, 4 months, 8 months, 12 months
Change in corneal curvature (CC)
Time frame: Baseline, 4 months, 8 months, 12 months
Change in choroidal thickness (CT)
Time frame: Baseline, 4 months, 8 months, 12 months
Change in White-to-White (WTW)
Time frame: Baseline, 4 months, 8 months, 12 months
Change in choroidal structures
Time frame: Baseline, 4 months, 8 months, 12 months
Intraocular pressure (IOP)
Time frame: Baseline, 4 months, 8 months, 12 months
Ocular and systemic symptoms
Time frame: Baseline, 4 months, 8 months, 12 months
Ocular signs assessed by slit-lamp biomicroscopy and binocular indirect ophthalmoscopy
Time frame: Baseline, 4 months, 8 months, 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Myopia
RecruitingPhase 3
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
Myopia
Not yet recruitingObservational study
Corneal Biomechanics and Stromal Tissue Characteristics in Patients Undergoing SMILE
Myopia
Enrolling by invitation
Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
Myopia
Not yet recruiting
Clinical Performance and Outcomes After Toric Lens Transition
Astigmatism
Active, not recruitingPhase 4
Odyssey Evaluation in Post LASIK Patients
Cataract
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yasmin Bradfield, MD principal investigator
University of Wisconsin, Madison
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Repeated Low-Level Red Light (RLRL) therapy in people with Myopia and Astigmatism, run by University of Wisconsin, Madison at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Angie Adler (608-265-7557, amadler1@wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cycloplegic spherical equivalent refraction (SER) (time frame: Baseline, 4 months, 8 months, 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.